2011
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression
Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecologic Oncology 2011, 125: 231-236. PMID: 22209775, PMCID: PMC3303974, DOI: 10.1016/j.ygyno.2011.12.446.Peer-Reviewed Original Research
2010
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro
Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecologic Oncology 2010, 119: 140-145. PMID: 20673976, PMCID: PMC2939197, DOI: 10.1016/j.ygyno.2010.06.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily B, Member 1Carcinoma, PapillaryCell Line, TumorCystadenocarcinoma, SerousDose-Response Relationship, DrugDrug Screening Assays, AntitumorEpothilonesFemaleHumansPaclitaxelReceptor, ErbB-2TubulinUterine NeoplasmsConceptsLow HER-2/neu expressionHER-2/neu expressionPrimary USPC cell linesUSPC cell linesUterine serous papillary carcinomaSensitivity/resistanceNeu expressionCell linesAggressive endometrial tumorsPromising novel drugSerous papillary carcinomaΒ-tubulin IIIQuantitative RT-PCRPaclitaxel chemotherapyAdverse prognosisCarcinoma cell linesEndometrial tumorsNeu overexpressionPapillary carcinomaUSPC patientsPatupilonePapillary carcinoma cell lineP-glycoproteinNovel drugsPaclitaxel